22Dec
Cadent Therapeutics Acquired by Novartis for Up to $770 Million
Cadent Therapeutics, a Cambridge, Massachusetts-based, privately held clinical stage biopharmaceutical company focused on the development of therapies for the treatment of cognitive, mood, and movement disorders, announced on December 17, 2020, that Novartis will acquire all of the outstanding capital stock of Cadent Therapeutics....
By:
Rothwell, Figg, Ernst & Manbeck, P.C.
Related
On June 13, 2019, the U.S. Court of Appeals for the Eighth Circuit affirmed a preliminary injunction...
Read More >
California employers need to pay heed to the recently announced California Division of Occupational ...
Read More >
On July 24th, Connecticut Governor Ned Lamont signed Executive Order No. 7JJJ, which creates a rebut...
Read More >
CONVERGE19 is in its 4th year of bringing together the world’s leading companies for 2 days of dyna...
Read More >
The beginning of 2021 should have marked the dawn of a new era. As the clocks turned past midnight, ...
Read More >
The Creation of the Contract-Generation Measure Introduces New Incentives for Hiring - New Legislat...
Read More >